Bitcoin price today: dips below $112k, near 6-wk low despite Fed cut bets
On Thursday, Raymond (NSE:RYMD) James affirmed a Strong Buy rating on Liquidia Technologies (NASDAQ:LQDA) with a consistent price target of $27.00. The firm’s confidence in the stock follows Liquidia’s fourth quarter financial results for 2024. According to InvestingPro data, analyst targets for LQDA range from $20 to $35, with the stock showing impressive momentum, gaining nearly 50% over the past six months. Analysts at Raymond James base their optimistic outlook on the expectation that Yutrepia, Liquidia’s product, will be launched for pulmonary arterial hypertension (PAH) and pulmonary hypertension in patients with interstitial lung disease (PH-ILD) around May 23, 2025.
Liquidia is set to begin its submission process for approval next week, with the timeframe starting March 24. This submission is strategically timed to align with the expiration of Tyvaso DPI™’s May 23 exclusivity under the National Coverage Indicator (NCI), which falls on a Friday before Memorial Day. Consequently, the earliest possible date for approval by the FDA could be Tuesday, May 27, given the holiday schedule. With a market capitalization of $1.26 billion and strong liquidity position (current ratio of 4.43x), InvestingPro analysis indicates the company is well-positioned to execute its launch plans.
New data is slated for presentation at the American Thoracic Society (ATS) conference in May. This includes results from the 6-minute walk test (6MWT), showing a 26.4-meter improvement from baseline in the first 20 patients at Week 8. Additional details on quality of life metrics and dosing clarity are also expected to be shared.
Management has indicated that the sales team, which has been operational for approximately 14 months, is well-prepared to commence immediate sales activities upon potential approval. This readiness is particularly pertinent in the PH-ILD market, where currently, only Tyvaso has received approval for treatment. While analysts project significant sales growth for the current year, InvestingPro data reveals additional insights about the company’s financial health and growth prospects in its comprehensive Pro Research Report, available along with 10+ exclusive ProTips for LQDA.
In other recent news, Liquidia Technologies Inc . reported its financial results for the fourth quarter of 2024, showing a net loss larger than analysts anticipated and revenue falling short of projections. The company posted a Q4 2024 earnings per share (EPS) of -$0.45, missing the forecast of -$0.3821, while revenue reached $2.92 million, significantly below the expected $4.54 million. For the full year, Liquidia’s revenue declined to $14 million from $17.5 million in 2023, with a net loss widening to $130.4 million. Despite these financial challenges, Liquidia secured $100 million in financing and plans to launch its key product, Eutrepia, in May 2025. The company remains optimistic about achieving profitability without further capital raises, supported by the recent financing. Analysts have noted the company’s strategic initiatives, including advancing the clinical profile of Eutrepia and expanding its commercial capabilities. Liquidia’s focus on obtaining FDA approval and launching new treatments in the pulmonary hypertension sector continues to be a priority amid regulatory hurdles and market competition.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.